These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22846203)

  • 1. Targeting mRNA splicing as a potential treatment for Duchenne muscular dystrophy.
    Kole R; Leppert BJ
    Discov Med; 2012 Jul; 14(74):59-69. PubMed ID: 22846203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Splicing intervention for Duchenne muscular dystrophy.
    McClorey G; Fletcher S; Wilton S
    Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
    Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
    Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro splicing analysis showed that availability of a cryptic splice site is not a determinant for alternative splicing patterns caused by +1G-->A mutations in introns of the dystrophin gene.
    Habara Y; Takeshima Y; Awano H; Okizuka Y; Zhang Z; Saiki K; Yagi M; Matsuo M
    J Med Genet; 2009 Aug; 46(8):542-7. PubMed ID: 19001018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
    Popplewell LJ; Graham IR; Malerba A; Dickson G
    Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duchenne and Becker muscular dystrophy: from gene diagnosis to molecular therapy.
    Matsuo M
    IUBMB Life; 2002 Mar; 53(3):147-52. PubMed ID: 12102170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
    Touznik A; Lee JJ; Yokota T
    Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.
    Takeshima Y; Yagi M; Wada H; Ishibashi K; Nishiyama A; Kakumoto M; Sakaeda T; Saura R; Okumura K; Matsuo M
    Pediatr Res; 2006 May; 59(5):690-4. PubMed ID: 16627883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances of treatment for Duchenne muscular dystrophy with exon skipping].
    Yang J; Zhang C
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Aug; 28(4):406-8. PubMed ID: 21811980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
    Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
    Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
    Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
    J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Point mutations in the dystrophin gene: evidence for frequent use of cryptic splice sites as a result of splicing defects.
    Tuffery-Giraud S; Chambert S; Demaille J; Claustres M
    Hum Mutat; 1999; 14(5):359-68. PubMed ID: 10533061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
    Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational development of splice-modifying antisense oligomers.
    Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
    Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA-targeted splice-correction therapy for neuromuscular disease.
    Wood MJ; Gait MJ; Yin H
    Brain; 2010 Apr; 133(Pt 4):957-72. PubMed ID: 20150322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy.
    Duan D
    Curr Opin Mol Ther; 2008 Feb; 10(1):86-94. PubMed ID: 18228186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ; Malerba A; Dickson G
    Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.